Pfizer Inc. (NYSE:PFE) Receives $31.92 Consensus Target Price from Analysts

Shares of Pfizer Inc. (NYSE:PFE) have been assigned a consensus rating of “Moderate Buy” from the sixteen analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, five have given a buy rating and three have given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $31.92.

A number of brokerages have weighed in on PFE. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the business. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE stock opened at $26.20 on Wednesday. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock’s 50 day moving average price is $26.17 and its 200 day moving average price is $27.04. The firm has a market cap of $148.61 billion, a P/E ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.